127 related articles for article (PubMed ID: 6952964)
1. VM26 in malignant hematological diseases. A phase II study.
Tirelli U; Carbone A; Franchin G; Galligioni E; Veronesi A; Trovo MG; Volpe R; Tumolo S; Grigoletto E
Cancer Chemother Pharmacol; 1982; 7(2-3):173-4. PubMed ID: 6952964
[TBL] [Abstract][Full Text] [Related]
2. Teniposide is not effective in chronic lymphocytic leukemia.
Zagonel V; Tirelli U; Veronesi A; Galligioni E; Tumolo S; Roncadin M; Carbone A; Grigoletto E
Blut; 1986 Jan; 52(1):59-61. PubMed ID: 3632912
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of teniposide (VM 26) in advanced non-Hodgkin's lymphoma, with emphasis on the treatment of elderly patients.
Tirelli U; Carbone A; Crivellari D; Volpe R; Franchin G; Veronesi A; Galligioni E; Trovò M; Tumolo S; Grigoletto E
Cancer; 1984 Aug; 54(3):393-6. PubMed ID: 6375853
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of teniposide (VM-26) in multiple myeloma.
Tirelli U; Carbone A; Zagonei V; Brema F; Veronesi A; Grigoletto E; Volpe R
Am J Clin Oncol; 1985 Aug; 8(4):329-31. PubMed ID: 3909805
[TBL] [Abstract][Full Text] [Related]
5. VM26 therapy in children with drug-refractory lymphocytic leukemia.
Rivera G; Dahl GV; Murphy SB; Bowman WP; Aur RJ; Avery TL; Simone JV
Cancer Chemother Pharmacol; 1982; 7(2-3):169-72. PubMed ID: 7083458
[No Abstract] [Full Text] [Related]
6. VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group Study (EST 1474).
Chiuten DF; Bennett JM; Creech RH; Glick J; Falkson G; Brodovsky HS; Begg CB; Muggia FM; Carbone PP
Cancer Treat Rep; 1979 Jan; 63(1):7-11. PubMed ID: 369693
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of teniposide (VM26) in cutaneous T-cell lymphomas.
Sorio R; Tirelli U; Zagonel V; Carbone A; Monfardini S
Am J Clin Oncol; 1990 Feb; 13(1):14-6. PubMed ID: 2305716
[TBL] [Abstract][Full Text] [Related]
8. Allergic reactions to teniposide in patients with neuroblastoma and lymphoid malignancies.
Hayes FA; Abromowitch M; Green AA
Cancer Treat Rep; 1985 Apr; 69(4):439-41. PubMed ID: 3857970
[TBL] [Abstract][Full Text] [Related]
9. [Results of a clinical study of an epipodophyllotoxin preparation (VM 26) in children with hemoblastoses].
Kondrat'eva NA; Makhonova LA; Maiakova SA; Vialushkin BIa
Probl Gematol Pereliv Krovi; 1981 Apr; 26(4):12-6. PubMed ID: 7015318
[No Abstract] [Full Text] [Related]
10. [Combination of adriamycin, VM 26, cyclophosphamide and prednisone in the treatment of hematosarcomas].
Laurens A; Thevenot J; Charron D; Jorry F; Dumonchel P; Martola R
Ann Med Interne (Paris); 1977 May; 128(5):493-6. PubMed ID: 334012
[No Abstract] [Full Text] [Related]
11. Severe hypertensive reactions to teniposide (VM-26) in infants with congenital leukemia.
Shimizu H; Frankel LS; Culbert SJ
Am J Pediatr Hematol Oncol; 1987; 9(3):239-41. PubMed ID: 3479027
[TBL] [Abstract][Full Text] [Related]
12. VM26: phase I and II studies.
Macbeth FR
Cancer Chemother Pharmacol; 1982; 7(2-3):87-91. PubMed ID: 7044595
[No Abstract] [Full Text] [Related]
13. Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy.
Giaccone G; Donadio M; Bonardi G; Testore F; Calciati A
J Clin Oncol; 1988 Aug; 6(8):1264-70. PubMed ID: 2842464
[TBL] [Abstract][Full Text] [Related]
14. Phase II evaluation of teniposide (VM-26) in metastatic breast carcinoma. A Southeastern Cancer Study Group trial.
Cox EB; Vogel CL; Carpenter JT; Raney M
Invest New Drugs; 1988 Apr; 6(1):37-9. PubMed ID: 3410666
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of teniposide in advanced breast cancer.
Boas J; Rasmussen D; Hansen OP; Engelholm SA; Dombernowsky P
Cancer Chemother Pharmacol; 1990; 25(6):463-4. PubMed ID: 2311176
[TBL] [Abstract][Full Text] [Related]
16. Phase I-II trial of VM-26 (NSC-122819) in the treatment of children with late-stage leukemia.
Rosenstock JG; Donaldson MH
Cancer Treat Rep; 1976 Mar; 60(3):265-7. PubMed ID: 1063066
[No Abstract] [Full Text] [Related]
17. Phase II study of VM-26 in acute leukemia, neuroblastoma, and other refractory childhood malignancies: a report from the Children's Cancer Study Group.
Bleyer WA; Krivit W; Chard RL; Hammond D
Cancer Treat Rep; 1979 Jun; 63(6):977-81. PubMed ID: 380803
[TBL] [Abstract][Full Text] [Related]
18. A case of small cell lung cancer successfully treated with VM26.
Suga J; Saijo N; Shinkai T; Eguchi K; Sasaki Y; Sakurai M; Sano T; Tamura T; Morinaga S
Jpn J Clin Oncol; 1986 Jun; 16(2):123-8. PubMed ID: 3016377
[TBL] [Abstract][Full Text] [Related]
19. Teniposide (VM26) as second-line treatment for small cell lung cancer.
Tummarello D; Guidi F; Torresi U; Dazzi C; Cellerino R
Anticancer Res; 1990; 10(2A):397-9. PubMed ID: 2161198
[TBL] [Abstract][Full Text] [Related]
20. Teniposide (VM26) disposition in children with leukemia.
Sinkule JA; Stewart CF; Crom WR; Melton ET; Dahl GV; Evans WE
Cancer Res; 1984 Mar; 44(3):1235-7. PubMed ID: 6581866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
